Product Code: CMI5718
Medications called serotonin norepinephrine inhibitors are similar to other antidepressant medications known as selective serotonin reuptake inhibitors (SSRIs). They both ease depression by affecting communication between brain nerve cells. However, SNRIs focus on two important brain chemicals-neurotransmitters-instead of just one. Serotonin norepinephrine inhibitors were developed in the mid-1990s and are prescribed to treat depression, anxiety disorders, and chronic pain, including neuropathic pain from diabetes or other chronic nerve conditions. They differ from SSRIs in that they also impact the levels of norepinephrine, which is involved with pain signals to body.
Market Dynamics:
The rise in the number of people suffering from depression globally is a major factor driving the growth of this market. According to World Health Organization, over 5.0% of the worldwide population suffers from depression. This number is expected to increase in the coming years, owing to various factors such as increasing social isolation and stressful work environment, which leads to the development of depression. The increase in the demand for effective treatment of depression is also propelling the growth of this market. In addition to this, the emergence of COVID-19 pandemic has increased the unemployment rate in several countries and has led to financial instability. This has resulted in a decrease in the household income, which is causing stress and anxiety among people. This in turn is increasing the demand for antidepressant drugs.
On the other hand, side effects associated with the drugs is expected to hamper the market growth.
Key features of the study:
- This report provides in-depth analysis of the global serotonin norepinephrine inhibitor market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global serotonin norepinephrine inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., Eli Lilly and Company, Allergan Plc., AstraZeneca Plc., Forest Laboratories Inc., Johnson & Johnson, Lundbeck A/S, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wyeth Pharmaceuticals Inc., and Zydus Cadila Healthcare Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global serotonin norepinephrine inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global serotonin norepinephrine inhibitor market
Detailed Segmentation:
- Global Serotonin Norepinephrine Inhibitor Market, By Application
- Depression
- Anxiety Disorders
- Chronic Pain
- Global Serotonin Norepinephrine Inhibitor Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Serotonin Norepinephrine Inhibitor Market, By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
- Company Profiles
- Pfizer Inc.
- Eli Lilly and Company
- Allergan Plc.
- AstraZeneca Plc.
- Forest Laboratories Inc.
- Johnson & Johnson
- Lundbeck A/S
- Merck & Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Wyeth Pharmaceuticals Inc.
- Zydus Cadila Healthcare Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Geography
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rise in the number of people suffering from depression
- Increase in the demand for effective treatment of depression
- Side effects associated with the medication
- Growing awareness regarding depression
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Serotonin Norepinephrine Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Serotonin Norepinephrine Inhibitor Market, By Application, 2017-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Bn)
- Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Bn)
- Chronic Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Bn)
6. Global Serotonin Norepinephrine Inhibitor Market, By Distribution Channel, 2017-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion)
7. Global Serotonin Norepinephrine Inhibitor Market, By Region, 2017-2030, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Country 2017 - 2030
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Bn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Bn)
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Bn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Bn)
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Bn)
8. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Allergan Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Forest Laboratories Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Torrent Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Wyeth Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Zydus Cadila Healthcare Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
9. Section
- Research Methodology
- About us